Lilly CFO Ashkenazi leaving to take job at Google parent Alphabet
Anat Ashkenazi was Lilly’s third-highest paid executive last year. She has worked at the company for 23 years, including as chief financial officer since 2021.
Eli Lilly and Co.
Articles
Britain poised to offer Eli Lilly’s weight-loss drug to patients
If the guidance is confirmed, Mounjaro will challenge the dominance of Novo’s Wegovy in the United Kingdom.
2024 Innovation Issue: How automation can be a lifesaver
Lilly plans to outfit its Lebanon plants—now under construction—with the latest in robotic, digital manufacturing equipment that will do much of the work that a generation ago was done by humans.
Lilly seeks to build conference center on downtown HQ campus
Eli Lilly and Co. plans to build the center on an existing parking lot at its downtown campus, with the goal of hosting more of its global meetings in Indianapolis.
Lilly to invest another $5.3B in Lebanon site to meet overwhelming demand for Mounjaro, Zepbound
Lilly said the new investment will allow it to hire 200 more workers at the complex, including engineers, scientists, and lab technicians, for a total of 900 full-time workers when it is fully operational.
China clears Eli Lilly’s weight-loss drug, only for diabetes now
The pharmaceutical weight-loss market is predicted to reach at least $100 billion by 2030, according to Goldman Sachs.
Lilly settles with spa selling knockoff versions of its popular diabetes, weight-loss drugs
In a series of lawsuits Lilly filed in September and October in federal court, the drugmaker had accused Totality Medispa of trademark infringement, false advertising, unfair competition and unfair trade practices.
Patients on hunt for diabetes, obesity and weight-loss drugs
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
Obesity drug rivals aim to unseat Zepbound, Ozempic
Eli Lilly and Novo are leading now, but there are multiple drug candidates waiting in the wings that could disrupt that duopoly in the future.
Indiana Fever lands Eli Lilly as jersey patch sponsor
Lilly and the Fever said they would also use the partnership “to close gaps on health outcomes in Indianapolis and across the state” by raising awareness of health issues.
Lilly sees quarterly profit jump 67% on demand for new weight-loss drugs
Doctors and pharmacies have reported huge demand for Mounjaro and Zepbound in recent months, causing widespread shortages of the popular drugs.
Lilly’s $3.7B manufacturing campus in Boone County starting to take shape
The company plans to develop at least 12 buildings totaling more than 1.6 million square feet. The project is expected to anchor the LEAP Research and Innovation District northwest of Lebanon.
Biden sees $35 price cap for insulin as pivotal campaign issue
Rarely a day goes without President Joe Biden mentioning insulin prices and promoting a $35 price cap for the medication for Americans on Medicare. The reality is more complicated.
Lilly weight-loss drug shows promise as a sleep apnea treatment in late-stage trials
Meanwhile, demand for Lilly’s Zephound and Mounjaro is leading to a shortage of the drugs that is expected to last until at least mid-year, the FDA said in an update Wednesday.
Lilly, Roche to get expedited FDA review for blood test to diagnose Alzheimer’s disease
Roche and Lilly said they believe the test could play an important role in improving access to early and accurate Alzheimer’s diagnosis.
No degree needed: Lilly hires more than 130 through Skills First program
Eli Lilly’s Skills First initiative is made up of four apprenticeship programs that prepare people for positions in manufacturing, IT, research labs, marketing, or administrative services.
Lilly jabs at people who use new weight-loss drugs ‘for vanity’
The Indianapolis-based drugmaker, which makes weight-loss drug Zepbound and diabetes drug Mounjaro, recently aired a new 30-second spot, just ahead of the Academy Awards, to underscore the message.
FDA delays Alzheimer’s drug for further review in surprise move
The call for additional scrutiny surprised Lilly executives, who noted that it is unusual for such a review to occur after the FDA has given an anticipated date to make a decision on approval. An OK for the drug had been expected this month.
New weight-loss drugs designed for long-term use, but some patients want to stop
Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy and Eli Lilly and Co.’s Mounjaro and Zepbound are finding out what happens when they stop taking them.
Lilly employees have seen big wins as stock price surges 500% since 2019
In the past 52 weeks, shares have set new records almost every week, due to investor eagerness over the company’s new drugs for obesity and diabetes, two health conditions that plague America, along with other drugs in the pipeline.